UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
UN General Assembly Demands Russia Return Ukrainian Children Amid Ongoing Conflict 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Meta Accused of Halting Internal Research on Mental Health Risks of Facebook and Instagram 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
European Stocks Rise as Markets Await Key U.S. Inflation Data 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Bristol Myers Squibb has sued AstraZeneca for its antibody-based cancer treatment Imjudo, which it says infringes its patents for its drug Yervoy
According to Bristol Myer, Imjudo fights cancer in the same way as Yervoy.
Bristol Myers has previously sued AstraZeneca for patent infringement over the latter’s other cancer drug, Imfinzi.
AstraZeneca said it is aware of the complaint and will respond to it "at the appropriate time."
The FDA has also approved the immunotherapy Yervoy for the treatment of kidney, lung, colorectal, and other cancers. The FDA initially approved Yervoy in 2011 to treat melanoma.
In 2021, Bristol Myers sold over $2 billion worth of Yervoy.
AstraZeneca’s Imjudo was given FDA approval last year to be used in conjunction with Imfinzi to treat liver and lung cancer.
In the second lawsuit, Bristol Myers claimed that AstraZeneca had violated two patents on the use of antibodies to treat cancer and strengthen a patient's immune system.
Bristol Myers insists that AstraZeneca was aware of the patents, being on notice due to licensing discussions and the Imfinzi lawsuit.
The lawsuit seeks an unspecified amount of money for damages.
